Clinical Trials Sponsored by Novartis+Pharmaceuticals

Total 21552 results

Novartis Pharmaceuticals

Completed

Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma

Thymoma

Germany
Novartis Pharmaceuticals

Completed

Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation

Renal Transplant

United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.

Renal Transplantation

France
Novartis Pharmaceuticals

Completed

Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease

Parkinson's Disease With End of Dose Wearing Off

United States, Puerto Rico
Novartis Pharmaceuticals

Terminated

Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles

Cystic Fibrosis

United States
Novartis Pharmaceuticals

Completed

Long-term Follow-up of Fingolimod Phase II Study Patients (ACROSS)

Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis

Spain, Canada, France, Switzerland, Italy, Portugal, Denmark, Poland, Germany, United Kingdom
Novartis Pharmaceuticals

Completed

Study of BGG492 in Patients With Chronic Subjective Tinnitus

Chronic Subjective Tinnitus

Germany, Netherlands
Novartis Pharmaceuticals

Completed

The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada

Cryopyrin Associated Periodic Syndrome

Canada
Novartis Pharmaceuticals

Completed

Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy

Cancer Prostate

Belgium
Novartis Pharmaceuticals

Completed

Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis

Prostate Cancer With Bone Metastasis
Novartis Pharmaceuticals

Completed

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Acromegaly

Germany
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients (HOSCAR)

Acromegaly

Italy, France, Portugal, Poland, Switzerland
Novartis Pharmaceuticals

Completed

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Neuroendocrine Tumors | Carcinoid

United States
Novartis Pharmaceuticals

Completed

A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (ENACT)

Chronic Myeloid Leukemia

Colombia, Venezuela
Novartis Pharmaceuticals

Terminated

A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics

Wet Age-related Macular Degeneration

United Kingdom
Novartis Pharmaceuticals

Completed

A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients

Neoplasms | Neoplasms by Site | Stomach Neoplasms | Stomach Diseases | Adenocarcinoma, Scirrhous | Linitis Plastica

Japan
Novartis Pharmaceuticals

Completed

Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases

Bone Neoplasms

Australia
Novartis Pharmaceuticals

Completed

Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

Myelodysplastic Syndromes | Beta-Thalassemia

Hungary
Novartis Pharmaceuticals

Completed

Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase ('MACS1252)

CML in Chronic Phase

Germany, Italy, Spain, Belgium, Croatia, Hungary, Netherlands, Austria, France, Greece, Sweden, Switzerland, Bulgaria, Romania, Slovenia, United Kingdom, Lithuania, Slovakia, Denmark, Finland, Norway, Poland, Czech Republic, Portugal, E... and more
Novartis Pharmaceuticals

Completed

Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women (PREDICT)

Locally Advanced Breast Cancer

Brazil
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)

Paget's Disease of Bone

China
Novartis Pharmaceuticals

Completed

Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer

Breast Cancer

Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients

Renal Transplantation
Novartis Pharmaceuticals

Completed

The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis

Prostate Cancer

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Imatinib in Chordoma

Chordoma

Switzerland, Italy
Novartis Pharmaceuticals

Completed

Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients

Kidney Transplantation

United States, Belgium
Novartis Pharmaceuticals

Completed

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Chronic Myelomonocytic Leukemia | Hypereosinophilic Syndrome | Systemic Mastocytosis | Dermatofibrosarcoma

Australia
Novartis Pharmaceuticals

Completed

A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients

Heart Transplantation

Spain, United States, Austria, Italy, Canada, Germany, Australia, Brazil
Novartis Pharmaceuticals

Completed

Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

Essential Hypertension

Japan
Novartis Pharmaceuticals

Completed

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

Transfusional Iron Overload

United States, Greece, Italy
Novartis Pharmaceuticals

Completed

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

Chronic Myelogenous Leukemia

Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib

Gastrointestinal Stromal Tumors

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia | Refractory Leukemia

Belgium, Korea, Republic of, Turkey, Germany, Australia, France, Switzerland, United Kingdom, Spain, Italy, Peru, United States
Novartis Pharmaceuticals

Completed

16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients (INSTINCT)

Alzheimer's Disease

China
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer

Breast Cancer

United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer (INV181)

Breast Cancer

Germany
Novartis Pharmaceuticals

Completed

Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States, Hong Kong, Taiwan, Korea, Republic of
Novartis Pharmaceuticals

Completed

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, Chronic

United States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
Novartis Pharmaceuticals

Completed

Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec

Beta Thalassemia Transfusion Dependent

Italy
Novartis Pharmaceuticals

Completed

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Adrenocortical Adenoma | Endometrial Stromal Sarcomas

Germany, United States, Korea, Republic of, Hungary, Italy, Slovakia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin

Diabetes Mellitus, Type 2

Germany, Switzerland
Novartis Pharmaceuticals

Completed

Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer (deFEND)

Endometrial Cancer

Germany
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

Diabetes Mellitus, Type 2

United States
Novartis Pharmaceuticals

Completed

Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients

Heart Transplantation

Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer

Advanced Gastric Cancer

Japan
Novartis Pharmaceuticals

Completed

Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)

Type 2 Diabetes

China
Novartis Pharmaceuticals

Completed

Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-old

Atopic Dermatitis

Spain
Novartis Pharmaceuticals

Completed

Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients

Hypertension

Russian Federation
Novartis Pharmaceuticals

Completed

Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF) (CONTROL FMF)

Colchicine Resistant/Intolerant Familial Mediterranean Fever

Israel
Novartis Pharmaceuticals

Completed

Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)

Allergic Asthma

Japan

3

Subscribe